- Home
- TCMD vs XFOR Comparison
TCMD vs XFOR Comparison
Compare TCMD & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCMD | XFOR |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.1M | 332.3M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | TCMD | XFOR |
|---|---|---|
| Price | $28.15 | $3.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $23.25 | ★ $28.50 |
| AVG Volume (30 Days) | 457.4K | ★ 564.6K |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.66 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $311,513,000.00 | $33,979,000.00 |
| Revenue This Year | $11.31 | $1,276.65 |
| Revenue Next Year | $8.83 | N/A |
| P/E Ratio | $36.20 | ★ N/A |
| Revenue Growth | 9.28 | ★ 2925.74 |
| 52 Week Low | $8.61 | $1.35 |
| 52 Week High | $28.04 | $26.83 |
Technical Indicators
Market Signals| Indicator | TCMD | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 76.59 | 51.09 |
| Support Level | $24.54 | $3.05 |
| Resistance Level | $28.04 | $4.07 |
| Average True Range (ATR) | 1.06 | 0.28 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 95.62 | 59.80 |
Price Performance
Historical ComparisonAbout TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.